



ELSEVIER

Diabetes Research and Clinical Practice 47 (2000) 227–229

DIABETES RESEARCH
AND
CLINICAL PRACTICE


www.elsevier.com/locate/diabres

Author index of volume 47

- Acosta, A.M., see Olmos, P. **47**, 169
Ahmad Dar, F., see Hamid Zargar, A. **47**, 135
Ahmad Laway, B., see Hamid Zargar, A. **47**, 135
Anttila, M., see Vääräsmäki, M. **47**, 111
Arriagada, P., see Olmos, P. **47**, 169
Bapat, M.M., see Inamdar, P.A. **47**, 217
Barney, S., see Dugoujon, J.M. **47**, 209
Bertelsmann, F.W., see Valk, G.D. **47**, 87
Bicho, M., see Marques, F. **47**, 191
Bode, B.W., T.M. Gross, K.R. Thornton, J.J. Mastrototaro, Erratum to “Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study”: [Diabetes Res. Clin. Pract. 46 (1999) 183–190] **47**, 225
Bouter, L.M., see Valk, G.D. **47**, 87
Burkey, J., see McInerney, M.F. **47**, 151
Cartwright, K., see Crook, M. **47**, 119
Chung, M.Y., see Lee, D.H. **47**, 15
Claro, J.C., see Olmos, P. **47**, 169
Crespo, M.E., see Marques, F. **47**, 191
Crook, M.A., S. Khandhadia, P. Lumb, A. Ridha, A. Hussain, No difference in serum sialic acid in Type 2 diabetic patients from the United Arab Emirates with and without diabetic retinopathy **47**, 147
Crook, M., K. Cartwright, P. Lumb, A. Worsley, Serum sialic acid in young type-1 diabetic patients **47**, 119
Czarnecki, E.M., see Gutt, M. **47**, 177
Davis, C.E., see Metcalf, P.A. **47**, 25
Davis, C.L., see Gutt, M. **47**, 177
Díaz, R., see Olmos, P. **47**, 169
Devasagayam, T.P.A., see Inamdar, P.A. **47**, 217
Dohi, K., see Kanauchi, M. **47**, 45
Doi, T., see Inoguchi, T. **47**, 37
Dugoujon, J.M., E. Guitard, M.T. Sénégas, M.P. Roth, A. Sanchez, S. Barney, D. Simon, L. Papoz, Genetic markers of immunoglobulins and diabetes mellitus in the multiracial population of New Caledonia **47**, 209
Egusa, G., see Okubo, M. **47**, 71
Emmerich, M., see Olmos, P. **47**, 169
Faridah, I., see Ismail, I.S. **47**, 57
Flynn, J.C., see McInerney, M.F. **47**, 151
Folsom, A.R., see Metcalf, P.A. **47**, 25
Fujishima, M., see Iino, K. **47**, 105
Fujita, R., see Shiba, T. **47**, 97
Futera, S., see Olmos, P. **47**, 169
Galer, B.S., A. Giana, M.P. Jensen, Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life **47**, 123
Giana, A., see Galer, B.S. **47**, 123
Grootenhuis, P.A., see Valk, G.D. **47**, 87
Gross, T.M., see Bode, B.W. **47**, 225
Guan, L., see McInerney, M.F. **47**, 151
Guitard, E., see Dugoujon, J.M. **47**, 209
Gutt, M., C.L. Davis, S.B. Spitzer, M.M. Llabre, M. Kumar, E.M. Czarnecki, N. Schneiderman, J.S. Skyler, J.B. Marks, Validation of the insulin sensitivity index (ISI_{0,120}): comparison with other measures **47**, 177
Hamid Zargar, A., A. Kariem Khan, S. Rashid Masoodi, B. Ahmad Laway, A. Iqbal Wani, M. Iftikhar Bashir, F. Ahmad Dar, Prevalence of Type 2 diabetes mellitus and impaired glucose tolerance in the Kashmir Valley of the Indian subcontinent **47**, 135
Hartikainen, A.-L., see Vääräsmäki, M. **47**, 111
Hayashi, Y., see Shiba, T. **47**, 97
Heiss, G., see Metcalf, P.A. **47**, 25
Hussain, A., see Crook, M.A. **47**, 147
Ichikawa, K., see Iino, K. **47**, 105
Iftikhar Bashir, M., see Hamid Zargar, A. **47**, 135
Iino, K., M. Yoshinari, H. Yoshizumi, K. Ichikawa, M. Iwase, M. Fujishima, Normal pressure hydrocephalus in diabetic patients with recurrent episodes of hypoglycemic coma **47**, 165

- Inada, H., see Nishimaki, K. 47, 49
- Inamdar, P.A., S.M. Kelkar, T.P.A. Devasagayam, M.M. Bapat, Apolipoprotein E polymorphism in non-insulin-dependent diabetics of Mumbai, India and its effect on plasma lipids and lipoproteins 47, 217
- Inoguchi, T., T. Yamashita, F. Umeda, H. Mihara, O. Nakagaki, K. Takada, T. Kawano, H. Murao, T. Doi, H. Nawata, High incidence of silent myocardial ischemia in elderly patients with non insulin-dependent diabetes mellitus 47, 37
- Inoue, M., see Shiba, T. 47, 97
- Iqbal Wani, A., see Hamid Zargar, A. 47, 135
- Ismail, I.S., W.M. Wan Nazaimoon, W.B. Wan Mohamad, R. Letchuman, M. Singaraveloo, R. Pendek, I. Faridah, R. Rasat, I.H. Sheriff, B.A.K. Khalid, Socioodemographic determinants of glycaemic control in young diabetic patients in peninsular Malaysia 47, 57
- Isshiki, G., see Nishimaki, K. 47, 49
- Iwamoto, Y., see Shiba, T. 47, 97
- Iwase, M., see Iino, K. 47, 105
- Janeway Jr., C.A., see McInerney, M.F. 47, 151
- Jensen, M.P., see Galer, B.S. 47, 123
- Kageyama, S., see Shiba, T. 47, 97
- Kanauchi, M., T. Kawano, K. Dohi, Association of *Chlamydia pneumoniae* infection with diabetic nephropathy 47, 45
- Kang, D.G., see Lee, D.H. 47, 15
- Kariem Khan, A., see Hamid Zargar, A. 47, 135
- Karlsson, M.G.E., J. Ludvigsson, The ABBOS-peptide from bovine serum albumin causes an IFN- γ and IL-4 mRNA response in lymphocytes from children with recent onset of type 1 diabetes 47, 199
- Kawamori, R., see Kinoshita, J. 47, 185
- Kawamura, T., see Nishimaki, K. 47, 49
- Kawano, T., see Inoguchi, T. 47, 37
- Kawano, T., see Kanauchi, M. 47, 45
- Kelkar, S.M., see Inamdar, P.A. 47, 217
- Khalid, B.A.K., see Ismail, I.S. 47, 57
- Khandhadia, S., see Crook, M.A. 47, 147
- Kinalski, I., see Krętowski, A. 47, 81
- Kinalski, M., see Krętowski, A. 47, 81
- Kinoshita, J., Y. Tanaka, M. Niwa, H. Yoshii, M. Takagi, R. Kawamori, Impairment of insulin-induced vasodilation is associated with muscle insulin resistance in type 2 diabetes 47, 185
- Kitamura, S., see Shiba, T. 47, 97
- Krętowski, A., J. Myśliwiec, M. Szelachowska, M. Kinalski, I. Kinalski, Nicotinamide inhibits enhanced in vitro production of interleukin-12 and tumour necrosis factor- α in peripheral whole blood of people at high risk of developing Type 1 diabetes and people with newly diagnosed Type 1 diabetes 47, 81
- Kumar, M., see Gutt, M. 47, 177
- Lee, D.H., M.Y. Chung, J.U. Lee, D.G. Kang, Y.W. Paek, Changes of glucose transporters in the cerebral adaptation to hypoglycemia 47, 15
- Lee, J.U., see Lee, D.H. 47, 15
- Lee, S.-H., I.-S. Park, Effects of soybean diet on the β cells in the streptozotocin treated rats for induction of diabetes 47, 1
- Letchuman, R., see Ismail, I.S. 47, 57
- Llabre, M.M., see Gutt, M. 47, 177
- Ludvigsson, J., see Karlsson, M.G.E. 47, 199
- Lumb, P., see Crook, M. 47, 119
- Lumb, P., see Crook, M.A. 47, 147
- Maiz, A., see Olmos, P. 47, 169
- Makino, F., see Shiba, T. 47, 97
- Marks, J.B., see Gutt, M. 47, 177
- Marques, F., M.E. Crespo, Z.I. Silva, M. Bicho, Insulin and high glucose modulation of phosphatase and reductase enzymes in the human erythrocytes: a comparative analysis in normal and diabetic states 47, 191
- Mastrototaro, J.J., see Bode, B.W. 47, 225
- McInerney, M.F., J. Burkey, L. Guan, J.C. Flynn, K.I. Oravecz, C.A. Janeway Jr., An islet-specific CD8 $^{+}$ T cell hybridoma generated from non-obese diabetic mice recognizes insulin as an autoantigen 47, 151
- Metcalf, P.A., A.R. Folsom, C.E. Davis, K.K. Wu, G. Heiss, Haemostasis and carotid artery wall thickness in non-insulin dependent diabetes mellitus 47, 25
- Mihara, H., see Inoguchi, T. 47, 37
- Morales, P., see Olmos, P. 47, 169
- Murao, H., see Inoguchi, T. 47, 37
- Myśliwiec, J., see Krętowski, A. 47, 81
- Nabeya, N., see Nishimaki, K. 47, 49
- Nakagaki, O., see Inoguchi, T. 47, 37
- Nawata, H., see Inoguchi, T. 47, 37
- Niihira, S., see Nishimaki, K. 47, 49
- Nishimaki, K., T. Kawamura, H. Inada, K. Yagawa, Y. Nose, N. Nabeya, G. Isshiki, N. Tatsumi, S. Niihira, HLA DPB1*0201 gene confers disease susceptibility in Japanese with childhood onset Type I diabetes, independent of HLA-DR and DQ genotypes 47, 49
- Niwa, M., see Kinoshita, J. 47, 185
- Nose, Y., see Nishimaki, K. 47, 49
- Okubo, M., M. Tokui, G. Egusa, M. Yamakido, Association of sex hormone-binding globulin and insulin resistance among Japanese-American subjects 47, 71
- Okuda, Y., see Shiba, T. 47, 97
- Olmos, P., S. Futers, A.M. Acosta, S. Siegel, A. Maiz, R. Schiaffino, P. Morales, R. Diaz, P. Arriagada, J.C. Claro, R. Vega, V. Vollrath, S. Velasco, M. Emmerich, (AC)₂₃ [Z - 2] polymorphism of the aldose reductase gene and fast progression of retinopathy in Chilean type 2 diabetics 47, 169
- Oravecz, K.I., see McInerney, M.F. 47, 151
- Paek, Y.W., see Lee, D.H. 47, 15
- Papoz, L., see Dugoujon, J.M. 47, 209
- Park, I.-S., see Lee, S.-H. 47, 1
- Pendek, R., see Ismail, I.S. 47, 57

- Pirttiaho, H., see Vääräsmäki, M. 47, 111
- Ramachandran, A., see Snehalatha, C. 47, 129
- Rasat, R., see Ismail, I.S. 47, 57
- Rashid Masoodi, S., see Hamid Zargar, A. 47, 135
- Ridha, A., see Crook, M.A. 47, 147
- Roth, M.P., see Dugoujon, J.M. 47, 209
- Sanchez, A., see Dugoujon, J.M. 47, 209
- Satyavani, K., see Snehalatha, C. 47, 129
- Schiaffino, R., see Olmos, P. 47, 169
- Schneiderman, N., see Gutt, M. 47, 177
- Sénégas, M.T., see Dugoujon, J.M. 47, 209
- Sheriff, I.H., see Ismail, I.S. 47, 57
- Shiba, T., M. Inoue, H. Tada, Y. Hayashi, Y. Okuda, R. Fujita, F. Makino, C. Takahasi, S. Kageyama, S. Kitamura, Y. Iwamoto, Delapril versus manidipine in hypertensive therapy to halt the type-2-diabetes-mellitus-associated nephropathy 47, 97
- Siegel, S., see Olmos, P. 47, 169
- Silva, Z.I., see Marques, F. 47, 191
- Simon, D., see Dugoujon, J.M. 47, 209
- Singaraveloo, M., see Ismail, I.S. 47, 57
- Skyler, J.S., see Gutt, M. 47, 177
- Snehalatha, C., A. Ramachandran, K. Satyavani, V. Vijay, Limitations of glycosylated haemoglobin as an index of glucose intolerance 47, 129
- Spitzer, S.B., see Gutt, M. 47, 177
- Szelachowska, M., see Krętowski, A. 47, 81
- Tada, H., see Shiba, T. 47, 97
- Takada, K., see Inoguchi, T. 47, 37
- Takagi, M., see Kinoshita, J. 47, 185
- Takahasi, C., see Shiba, T. 47, 97
- Tanaka, Y., see Kinoshita, J. 47, 185
- Tatsumi, N., see Nishimaki, K. 47, 49
- Thornton, K.R., see Bode, B.W. 47, 225
- Tokui, M., see Okubo, M. 47, 71
- Umeda, F., see Inoguchi, T. 47, 37
- Vääräsmäki, M., A.-L. Hartikainen, M. Anttila, H. Pirttiaho, Out-patient management does not impair outcome of pregnancy in women with type 1 diabetes 47, 111
- Valk, G.D., P.A. Grootenhuis, J.T.M. van Eijk, L.M. Bouter, F.W. Bertelsmann, Methods for assessing diabetic poly neuropathy: validity and reproducibility of the measurement of sensory symptom severity and nerve function tests 47, 87
- van Eijk, J.T.M., see Valk, G.D. 47, 87
- Vega, R., see Olmos, P. 47, 169
- Velasco, S., see Olmos, P. 47, 169
- Vijay, V., see Snehalatha, C. 47, 129
- Vollrath, V., see Olmos, P. 47, 169
- Wan Mohamad, W.B., see Ismail, I.S. 47, 57
- Wan Nazaimoon, W.M., see Ismail, I.S. 47, 57
- Worsley, A., see Crook, M. 47, 119
- Wu, K.K., see Metcalf, P.A. 47, 25
- Yagawa, K., see Nishimaki, K. 47, 49
- Yamakido, M., see Okubo, M. 47, 71
- Yamashita, T., see Inoguchi, T. 47, 37
- Yoshii, H., see Kinoshita, J. 47, 185
- Yoshinari, M., see Iino, K. 47, 105
- Yoshizumi, H., see Iino, K. 47, 105





ELSEVIER

Diabetes Research and Clinical Practice 47 (2000) 231–234

DIABETES RESEARCH
AND
CLINICAL PRACTICE

www.elsevier.com/locate/diabres

Subject index of volume 47

ABBOS; IFN- γ ; IL-4; Type 1 diabetes; Th-lymphocytes **47**, 199

Activation induced cell death (AICD); Non-obese diabetic (NOD) mice; T cell hybridoma; CD8 $^{+}$ T cells; Antigen presenting cells (APC) **47**, 151

Aldose reductase; Variable number tandem repeats; Polymerase chain reaction **47**, 169

Antigen presenting cells (APC); Non-obese diabetic (NOD) mice; T cell hybridoma; CD8 $^{+}$ T cells; Activation induced cell death (AICD) **47**, 151

ApoE polymorphism; NIDDM; Lipoproteins; Hypercholesterolemia; Hypertriglyceridemia **47**, 217

B-mode ultrasound; Plasma fibrinogen; Carotid atherosclerosis; NIDDM **47**, 25

Brain atrophy; Hypoglycemic coma; Normal pressure hydrocephalus; RI cisternography **47**, 105

Brain; Glucose transporter; Hypoglycemia **47**, 15

Carotid atherosclerosis; B-mode ultrasound; Plasma fibrinogen; NIDDM **47**, 25

CD8 $^{+}$ T cells; Non-obese diabetic (NOD) mice; T cell hybridoma; Activation induced cell death (AICD); Antigen presenting cells (APC) **47**, 151

Chlamydia pneumoniae; Diabetic nephropathy; Renal biopsy **47**, 45

Congenital malformation; Diabetes; Glycaemic control; Perinatal mortality rate; Pregnancy **47**, 111

Coronary angiography; Silent myocardial ischemia; Elderly

NIDDM patients; Treadmill exercise test; Dipyridamole thallium scintigraphy **47**, 37

Delapril; Hypertension; Type 2 diabetes mellitus; Diabetic nephropathy; Manidipine **47**, 97

Diabetes care facilities; Diabetic control; Socioeconomic factors; Malaysia **47**, 57

Diabetes; Congenital malformation; Glycaemic control; Perinatal mortality rate; Pregnancy **47**, 111

Diabetes mellitus; Glucose; Insulin; Insulin receptor phosphorylation; Phosphatase activity; Human erythrocytes **47**, 191

Diabetes mellitus; New Caledonia; Immunoglobulins; GM and KM allotypes **47**, 209

Diabetes mellitus; Pain; Neuropathy; Quality of life **47**, 123

Diabetes mellitus; Sialic acid; Retinopathy disease **47**, 147

Diabetes; Soybean diet; Pancreas; Insulin mRNA; Insulin secretion **47**, 1

Diabetic control; Socioeconomic factors; Diabetes care facilities; Malaysia **47**, 57

Diabetic nephropathy; *Chlamydia pneumoniae*; Renal biopsy **47**, 45

Diabetic nephropathy; Hypertension; Type 2 diabetes mellitus; Manidipine; Delapril **47**, 97

Diabetic polyneuropathy; Sensory symptoms; Nerve function tests **47**, 87

Diagnostic criterion; Glycated haemoglobin; HbA_{1c}; Glucose intolerance **47**, 129

- Dipyridamole thallium scintigraphy;** Silent myocardial ischemia; Elderly NIDDM patients; Treadmill exercise test; Coronary angiography **47**, 37
- DPB1*0201;** Type I diabetes; Susceptibility; Human leukocyte antigen **47**, 49
- Elderly NIDDM patients;** Silent myocardial ischemia; Treadmill exercise test; Dipyridamole thallium scintigraphy; Coronary angiography **47**, 37
- Euglycemic clamp;** Insulin sensitivity; Validity; Glucose uptake; Oral glucose tolerance test **47**, 177
- Euglycemic hyperinsulinemic glucose clamp;** Insulin; Vasodilation; Insulin sensitivity; Type 2 diabetes **47**, 185
- Glucose;** Insulin; Diabetes mellitus; Insulin receptor phosphorylation; Phosphatase activity; Human erythrocytes **47**, 191
- Glucose intolerance;** Glycated haemoglobin; HbA_{1c}; Diagnostic criterion **47**, 129
- Glucose transporter;** Brain; Hypoglycemia **47**, 15
- Glucose uptake;** Insulin sensitivity; Validity; Euglycemic clamp; Oral glucose tolerance test **47**, 177
- Glycaemic control;** Congenital malformation; Diabetes; Perinatal mortality rate; Pregnancy **47**, 111
- Glycated haemoglobin;** HbA_{1c}; Diagnostic criterion; Glucose intolerance **47**, 129
- GM and KM allotypes;** Diabetes mellitus; New Caledonia; Immunoglobulins **47**, 209
- HbA_{1c};** Glycated haemoglobin; Diagnostic criterion; Glucose intolerance **47**, 129
- Homeostasis model assessment;** Sex hormone-binding globulin; Insulin resistance; Japanese-Americans **47**, 71
- Human erythrocytes;** Glucose; Insulin; Diabetes mellitus; Insulin receptor phosphorylation; Phosphatase activity **47**, 191
- Human leukocyte antigen;** Type I diabetes; Susceptibility; DPB1*0201 **47**, 49
- Hypercholesterolemia;** ApoE polymorphism; NIDDM; Lipoproteins; Hypertriglyceridemia **47**, 217
- Hypertension;** Type 2 diabetes mellitus; Diabetic nephropathy; Manidipine; Delapril **47**, 97
- Hypertriglyceridemia;** ApoE polymorphism; NIDDM; Lipoproteins; Hypercholesterolemia **47**, 217
- Hypoglycemia;** Brain; Glucose transporter **47**, 15
- Hypoglycemic coma;** Normal pressure hydrocephalus; Brain atrophy; RI cisternography **47**, 105
- IFN-γ;** ABBOS; IL-4; Type 1 diabetes; Th-lymphocytes **47**, 199
- IL-4;** ABBOS; IFN-γ; Type 1 diabetes; Th-lymphocytes **47**, 199
- Immunoglobulins;** Diabetes mellitus; New Caledonia; GM and KM allotypes **47**, 209
- Impaired glucose tolerance;** Known diabetes; Type 2 diabetes; Prevalence **47**, 135
- Insulin;** Glucose; Diabetes mellitus; Insulin receptor phosphorylation; Phosphatase activity; Human erythrocytes **47**, 191
- Insulin mRNA;** Soybean diet; Diabetes; Pancreas; Insulin secretion **47**, 1
- Insulin receptor phosphorylation;** Glucose; Insulin; Diabetes mellitus; Phosphatase activity; Human erythrocytes **47**, 191
- Insulin resistance;** Sex hormone-binding globulin; Homeostasis model assessment; Japanese-Americans **47**, 71
- Insulin secretion;** Soybean diet; Diabetes; Pancreas; Insulin mRNA **47**, 1
- Insulin sensitivity;** Insulin; Vasodilation; Type 2 diabetes; Euglycemic hyperinsulinemic glucose clamp **47**, 185
- Insulin sensitivity;** Validity; Glucose uptake; Euglycemic clamp; Oral glucose tolerance test **47**, 177
- Insulin;** Vasodilation; Insulin sensitivity; Type 2 diabetes; Euglycemic hyperinsulinemic glucose clamp **47**, 185
- Interleukin-12;** Type 1 diabetes; Nicotinamide; Tumour necrosis factor-α **47**, 81
- Japanese-Americans;** Sex hormone-binding globulin; Homeostasis model assessment; Insulin resistance **47**, 71
- Known diabetes;** Impaired glucose tolerance; Type 2 diabetes; Prevalence **47**, 135
- Lipoproteins;** ApoE polymorphism; NIDDM; Hypercholesterolemia; Hypertriglyceridemia **47**, 217
- Malaysia;** Diabetic control; Socioeconomic factors; Diabetes care facilities **47**, 57
- Manidipine;** Hypertension; Type 2 diabetes mellitus; Diabetic nephropathy; Delapril **47**, 97

- Nerve function tests;** Diabetic polyneuropathy; Sensory symptoms **47, 87**
- Neuropathy;** Diabetes mellitus; Pain; Quality of life **47, 123**
- New Caledonia;** Diabetes mellitus; Immunoglobulins; GM and KM allotypes **47, 209**
- Nicotinamide;** Type 1 diabetes; Interleukin-12; Tumour necrosis factor- α **47, 81**
- NIDDM;** ApoE polymorphism; Lipoproteins; Hypercholesterolemia; Hypertriglyceridemia **47, 217**
- NIDDM;** B-mode ultrasound; Plasma fibrinogen; Carotid atherosclerosis **47, 25**
- Non-obese diabetic (NOD) mice;** T cell hybridoma; CD8⁺ T cells; Activation induced cell death (AICD); Antigen presenting cells (APC) **47, 151**
- Normal pressure hydrocephalus;** Hypoglycemic coma; Brain atrophy; RI cisternography **47, 105**
- Oral glucose tolerance test;** Insulin sensitivity; Validity; Glucose uptake; Euglycemic clamp **47, 177**
- Pain;** Diabetes mellitus; Neuropathy; Quality of life **47, 123**
- Pancreas;** Soybean diet; Diabetes; Insulin mRNA; Insulin secretion **47, 1**
- Perinatal mortality rate;** Congenital malformation; Diabetes; Glycaemic control; Pregnancy **47, 111**
- Phosphatase activity;** Glucose; Insulin; Diabetes mellitus; Insulin receptor phosphorylation; Human erythrocytes **47, 191**
- Plasma fibrinogen;** B-mode ultrasound; Carotid atherosclerosis; NIDDM **47, 25**
- Polymerase chain reaction;** Aldose reductase; Variable number tandem repeats **47, 169**
- Pregnancy;** Congenital malformation; Diabetes; Glycaemic control; Perinatal mortality rate **47, 111**
- Prevalence;** Impaired glucose tolerance; Known diabetes; Type 2 diabetes **47, 135**
- Quality of life;** Diabetes mellitus; Pain; Neuropathy **47, 123**
- Renal biopsy;** *Chlamydia pneumoniae*; Diabetic nephropathy **47, 45**
- Retinopathy disease;** Diabetes mellitus; Sialic acid **47, 147**
- RI cisternography;** Hypoglycemic coma; Normal pressure hydrocephalus; Brain atrophy **47, 105**
- Sensory symptoms;** Diabetic polyneuropathy; Nerve function tests **47, 87**
- Serum sialic acid;** Type-1 diabetes mellitus; Young patients **47, 119**
- Sex hormone-binding globulin;** Homeostasis model assessment; Insulin resistance; Japanese-Americans **47, 71**
- Sialic acid;** Diabetes mellitus; Retinopathy disease **47, 147**
- Silent myocardial ischemia;** Elderly NIDDM patients; Treadmill exercise test; Dipyridamole thallium scintigraphy; Coronary angiography **47, 37**
- Socioeconomic factors;** Diabetic control; Diabetes care facilities; Malaysia **47, 57**
- Soybean diet;** Diabetes; Pancreas; Insulin mRNA; Insulin secretion **47, 1**
- Susceptibility;** Type I diabetes; Human leukocyte antigen; DPB1*0201 **47, 49**
- T cell hybridoma;** Non-obese diabetic (NOD) mice; CD8⁺ T cells; Activation induced cell death (AICD); Antigen presenting cells (APC) **47, 151**
- Th-lymphocytes;** ABBOS; IFN- γ ; IL-4; Type 1 diabetes **47, 199**
- Treadmill exercise test;** Silent myocardial ischemia; Elderly NIDDM patients; Dipyridamole thallium scintigraphy; Coronary angiography **47, 37**
- Tumour necrosis factor- α ;** Type 1 diabetes; Nicotinamide; Interleukin-12 **47, 81**
- Type 1 diabetes;** ABBOS; IFN- γ ; IL-4; Th-lymphocytes **47, 199**
- Type 2 diabetes;** Impaired glucose tolerance; Known diabetes; Prevalence **47, 135**
- Type 2 diabetes;** Insulin; Vasodilation; Insulin sensitivity; Euglycemic hyperinsulinemic glucose clamp **47, 185**
- Type 2 diabetes mellitus;** Hypertension; Diabetic nephropathy; Manidipine; Delapril **47, 97**
- Type-1 diabetes mellitus;** Serum sialic acid; Young patients **47, 119**
- Type 1 diabetes;** Nicotinamide; Interleukin-12; Tumour necrosis factor- α **47, 81**

Type I diabetes; Susceptibility; Human leukocyte antigen; DPB1*0201 **47**, 49

Validity; Insulin sensitivity; Glucose uptake; Euglycemic clamp; Oral glucose tolerance test **47**, 177

Variable number tandem repeats; Aldose reductase; Polymerase chain reaction **47**, 169

Vasodilation; Insulin; Insulin sensitivity; Type 2 diabetes; Euglycemic hyperinsulinemic glucose clamp **47**, 185

Young patients; Serum sialic acid; Type-1 diabetes mellitus **47**, 119

